Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.

Related Keywords

Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Hebron ,Israel General ,Israel ,Daiichi Sankyo Astrazeneca ,Mafalda Oliveira ,Pfizer ,Genentech ,Breast Cancer Congress ,Novartis ,Astrazeneca ,Hebron University Hospital ,Breast Cancer Group ,Hebron Institute Of Oncology ,Oncology Department Of The Breast Cancer Group ,Ayala Pharmaceuticals ,Medical Oncology Department ,University Hospital ,Hebron Institute ,Zenith Epigenetics ,Cureos Science ,Relay Therapeutics ,